While erlotinib, an EGFR tyrosine kinase inhibitor, acts through a different mechanism, curcumin’s modulation of NF-κB offers a complementary approach, potentially overcoming the limitations of current GBM therapies [95]. This evidence concerns the gene NFKB1 and glioblastoma.